Transcranial Electrical Stimulation for Treating Chronic Pain in Inflammatory Demyelinating Diseases
RecruitingNot applicableNCT06942611
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Non-invasive neurostimulation can effectively improve patients' symptoms and has shown good therapeutic efficacy in alleviating the symptoms of IIDDs (Inflammatory Immune-mediated Demyelinating Diseases). However, some patients have not achieved the desired results, which may be due to individual differences in neural responsiveness . Therefore, this study aims to assess the therapeutic effect of transcranial electrical stimulation on improving symptoms such as painful spasm in IIDDs patients, by considering both the overall characteristics of IIDDs disease symptoms and individual differences in patients. The study will explore the imaging characteristics, electrophysiological features of the disease symptoms, and their relationship with clinical manifestations, while analyzing the key factors that influence treatment efficacy.
Study details
- Official title
- A Study on the Therapeutic Effects of Transcranial Electrical Stimulation Combined on Chronic Pain in Central Nervous System Inflammatory Demyelinating Diseases
- Conditions
- Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
- Interventions
- Device: transcranial electrical stimulation treatment.
- Sponsor
- Xuanwu Hospital, Beijing
- Start date
- 2025-05-03
- Primary completion
- 2027-07-31
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: Patients diagnosed with neuromyelitis optica spectrum disorder, multiple sclerosis, or other central nervous system inflammatory demyelinating diseases that meet the diagnostic criteria; Numeric Rating Scale (NRS) pain score ≥4; Age between 18 and 65 years, regardless of gender; Stable dose of immunosuppressive therapy for at least one month; EDSS score ≤6; Right-handed; Agree to participate and sign the informed consent form. Exclusion Criteria: A history of relapse within the past month; Recent medication adjustments or treatment with modified electroconvulsive therapy, transcranial magnetic stimulation, or other neurostimulation techniques within the past month; Participation in any other clinical trial within the past month or currently participating in another clinical trial; Presence of cochlear implants, pacemakers, or implanted stimulators in the brain; Skin integrity at the electrode placement site is compromised, or allergy to electrode gel or adhesive; A history of epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infections; Pregnant or breastfeeding women, or those planning to become pregnant in the near future; A score of ≥3 on item 3 (suicide item) of the HDRS-17, or a history of severe psychiatric disorders; Presence of severe or unstable organic diseases; Poor patient compliance preventing cooperation with treatment, follow-up, or clinical, EEG, and imaging data collection; Any other situation deemed unsuitable for participation in the study by the investigator.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06942611